Zenodo · Apr 20, 2026
APROS-SYBEL KRONOS-NANO APROS- BÜTÜNSEL BİYOLOJİ
By yünlü ME
APROS, SYBEL-KRONOS, NANO-APROS, and Disease Categories – Defensive Publications (Prior Art) Published by: Muzaffer Enes Yünlü License: CC BY-NC-SA 4.0 Legal status: Publicly available technical document – constitutes prior art under patent law --- What are these documents? These are defensive publications describing concrete technical systems in synthetic biology, epigenetic reset, nanotechnology, and programmable cell-based therapies. Their purpose is to prevent others from patenting these systems and to keep them in the public domain. The documents define four main systems: 1. APROS-V9.5 – Adaptive Performance and Recursive OS · 18 biomarkers with dynamic threshold function · 5 intervention phases (F0–F5) · 4-layer kill-switch · 120 valid phase sequences · Epigenetic reset (OSKM/OSK modRNA) 2. SYBEL-KRONOS V2.0 – Synthetic biology logic circuits for living cells · 3 concrete circuits (diabetes, inflammation, DNA damage) · AND / OR gates · 3 memory mechanisms (DNA methylation, flip-flop, CRISPRi) 3. NANO-APROS V2.0 – Single nanoparticle with 7 defined layers · 8 concrete examples (pancreatic cancer, Alzheimer, COVID-19, diabetes, heart attack, hepatitis B, rheumatoid arthritis, liver fibrosis) · Sensors: pH, ROS, ATP, IL-6, CRP, TGF-β, HBsAg, glucose · Negative selection ligands (SEQ ID NO: 1–5) 4. APROS-NANO-SYBEL – 15 Disease Categories · Application of the above three systems to 15 disease categories · One concrete example per category · Cancers, neurodegeneration, autoimmune, metabolic, cardiovascular, infections, fibrosis, genetic diseases, aging, psychiatric, eye, kidney, respiratory, rare diseases --- What is considered prior art? · The 3 circuits, 8 nanoparticle examples, and 15 disease categories explicitly defined · Obvious variations (under KSR v. Teleflex, 2007): · ±20% change in threshold values · Substitution of similar cell lines or nanoparticle materials · Routine dose optimization · Other diseases within the same category (e.g., breast cancer, Parkinson’s, lupus) · Kill-switch: 4 layers and 15 sub‑combinations · modRNA protocol: CleanCap AG, N1-methyl-pseudo-UTP, α-globin UTR, 120 nt polyA · LNP formulation: DSPC:cholesterol:DOPE:PEG (25:40:25:10), 80±20 nm --- What is NOT covered (limitation)? · Diseases or systems outside the 3 circuits / 8 examples / 15 categories · The full list of 256 biomarkers (only 6 have concrete measurement methods) · Any efficacy claim (e.g., “this cures cancer”) – only “if X then Y” logic is defined · Nanoparticles with different numbers of layers · Kill-switch mechanisms outside APROS-V9.5 --- Who is this for? · Patent offices and prior art examiners · Synthetic biologists, molecular biologists, nanotech researchers · Open science advocates and independent researchers · Anyone who might otherwise try to patent these obvious variations --- How to cite? Yünlü, M. E. (2026). APROS-V9.5: Defensive Publication and Prior Art Document. Zenodo. https://doi.org/10.5281/zenodo.19428077 Yünlü, M. E. (2026). SYBEL-KRONOS V2.0: Defensive Publication and Prior Art Document. Zenodo. (same DOI family) Yünlü, M. E. (2026). NANO-APROS V2.0: Defensive Publication and Prior Art Document. Zenodo. https://doi.org/10.5281/zenodo.19572973 Yünlü, M. E. (2026). APROS-NANO-SYBEL: Expansion to Disease Categories. Zenodo. --- Not / Note: Bu dokümanda tanımlanmayan hiçbir şey için prior art iddiasında bulunulmaz. No prior art is claimed for anything not explicitly defined in these documents. --